Active control cancer trials
Executive Summary
Design and analysis of active control trials added to the agenda for the Dec. 14 meeting of FDA's Oncologic Drugs Advisory Committee at the Holiday Inn in Bethesda, Md., beginning at 8:00 a.m. Review of Searle's Celebrex for the regression and prevention of adenomatous polyps which may lead to the development of colorectal cancer in patients with familial adenomatous polyposis will begin at approximately 10:00 a.m. The Dec. 13 agenda remains unchanged: Rhone-Poulenc Rorer's Taxotere for the new indication of metastatic non-small cell lung cancer and Ligand's Targretin for cutaneous T-cell lymphoma
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth